Relationship between obesity and pancreatitis

Sarah Navina MD[1], Vijay P. Singh MD[2]

[1]Clin-Path Associates, Tempe AZ. [2]Mayo Clinic, Scottsdale, AZ.

e-mail: Singh.Vijay@mayo.edu

Acute pancreatitis (AP) has several etiologies and diverse outcomes. The outcomes may range from spontaneous resolution of an acute attack which may never recur again, to a disease which over a few days may progress to severe acute pancreatitis (SAP) resulting in prolonged hospitalization for local or systemic complications, and sometimes mortality. Several studies have reported obese patients, who have increased visceral fat depots, including pancreatic fat, as being at risk of SAP (1, 22, 37, 42, 89, 95, 100, 109, 117, 119, 149). Repeated attacks of AP may result in a clinical picture of recurrent acute pancreatitis which may progress to chronic pancreatitis (CP) with an associated increased in pancreatic fat (70, 86, 146). However, while being potentially debilitating due to pain, exocrine insufficiency, diabetes or quality of life issues, recurrent acute or chronic pancreatitis rarely result in SAP (70, 87, 92).

SAP typically occurs during the first or second AP attack (2, 70). The disease spectrum of SAP includes local complications, primarily pancreatic necrosis (PN) and peripancreatic necrosis (PPN) which sometimes get infected, and systemic complications including organ failure involving the respiratory, renal systems and a shock like state. Local complications from extensive PN or PPN, or systemic complications lasting > 48 hours (sustained organ failure) or involving more than one organ system (multisystem organ failure) can result in prolonged hospitalization or mortality. While obese patients are prone to both local and systemic compilations in AP, no consistent relationship has been reported between the etiology of AP and SAP (21, 116, 137, 143) with the exception of hypertriglyceridemic pancreatitis (31, 33, 72). This association and reports that obese patients may have worse outcomes in AP suggest a common lipid related modifier to alter the course of acute pancreatitis for the worse. Over the last 150 years, investigators have repeatedly broached the role of fat and the cells that contain it i.e. adipocytes in pancreatitis. The reports have ranged from gross descriptions of the appearance of the peritoneal cavity in patients dying from severe pancreatitis to the molecular mechanisms by which fatty acids may mediate these outcomes. Within this spectrum are studies of the influence of adipocytes on the histological appearance of pancreatitis, animal models of obesity and pancreatitis and cell culture models of lipotoxicity. In this chapter we will systematically explore the role that fat may play in the outcomes of pancreatitis especially in the context of obesity.

1. Historical Perspective

The relevance of obesity to acute pancreatitis was first documented in the 19th century. Balser in 1882 first indicated the presence of fat necrosis in acute pancreatitis (7). In 1889, while writing on acute pancreatitis in the *Medical Monographs,* Dr. Reginald Fitz quotes Zenker as stating "An excessive growth of the fat cells near the pancreas occurs in many men. It may become so excessive, in very fat people, that a large part of the abdominal

fat dies, and if this proves fatal, whether on account of the quantity destroyed or the associated hemorrhage" (39). Simon Flexner is 1896 was the first to suggest the role of lipases in pancreatitis associated fat damage (94). While Fitz mentions that Hans Chiari also noted the association between fat and pancreatitis (39), Chiari, widely known for the hypothesis of the pancreas auto digesting itself during pancreatitis (thus pioneering the proteolytic hypothesis of pancreatitis), published only later on this topic (23) as did others (53). More details of the early observations of fat in pancreatitis are mentioned in the work by Dr. Fitz (39) and are well summarized in more recent reviews (94).

Chemical analysis of pancreatic fat necrosis was initially performed in the early part of the 20th century (50) and revealed this to be predominantly free fatty acids with some saponification and calcium soaps. In the 1970s several independent investigators systematically explored the association between fat and pancreatitis. There were several elegant studies on the lipolytic pathogenesis (126), morphology (122) hypocalcemic complications (126) and therapeutic interventions (125) in animal models of fat necrosis. Quantification of fat cells in the pancreata of humans at autopsy showed the adipocyte amount to increase with body weight (90, 113). Studies in the 1980's by Schmitz-Moormann on pancreatic tissue from patients with acute pancreatitis showed pancreatic parenchymal and vascular damage to be in close proximity to fat cell necrosis (112). Kloppel made similar observations (67) in the peripancreatic fat of patients with acute pancreatitis, and both investigators hypothesized fat necrosis to be the initiating factor in human pancreatitis. This topic was debated and contrasted to the ubiquitous nature of active proteases in all models of pancreatitis, while the earlier use of pharmacologic protease inhibitors like trasylol and gabexate focused attention on proteases (129-131) preceding the focus on lipases. However as we have learnt over time, targeting proteases has provided no clinically

relevant improvement in outcomes (4, 16, 118). The discovery of the lipase inhibitor tetra-hydrolipistatin (THL) in the 1980s, from which orlistat is derived renewed interest in understanding the role of lipolysis in pancreatitis. *In vitro* studies by Mossner et al in the 1990s showed a protective effect of lipase inhibition on pancreatic acinar cells *in vitro* (81) but not when pancreatitis was induced by infusing bile salts such as sodium taurocholate into the pancreatic ducts of rats (65). Subsequent to this, there was a gap in the pursuit of systematic studies on the role of fat in pancreatitis, however the steady stream of clinical reports repeatedly mentioning intrabdominal fat/ viseral fat/obesity as being risk factor for SAP over this time has revived interest in this topic as we will discuss below.

2. Epidemiology of Obesity and Pancreatitis

Several studies have associated obesity or increased intra-abdominal fat with SAP (1, 22, 37, 42, 89, 95, 100, 109, 117, 119, 149). Body mass index (BMI) is commonly used as a measure of body fat amount. Apart from BMI, visceral adipose tissue, as measured by waist-to-hip ratio and waist circumference above ideal cut-off value have been proposed as risk factor for worse outcomes in AP (73, 76). Waist circumference has been shown to correlate with intra-abdominal fat volume (17) and is reported as being a risk factor for SAP (109).

Obesity is defined as a BMI of >30 kg/m^2 in the western hemisphere or >25 kg/m^2 in the East including countries such as Japan, Korea, China and India. Studies exploring the association of BMI with SAP from these regions commonly correlate severity of AP to these BMI cut offs. BMIs >30kg/m^2 are mentioned as being associated with SAP in reports from north America and Europe (15, 49, 62, 63, 100, 117) while reports from Asia mention BMIs > 23-25 kg/m^2 (119, 124, 148, 149) to be associated with SAP. The reason for this association is unclear. Previous studies have shown that fat composition in humans is related to

the fat composition of their diets. This observation may link the eastern diets and the visceral adipose tissue of the populations that consume these diets to be richer in unsaturated fatty acids particularly poly unsaturated fatty acids (PUFA) (58, 108, 115, 134) compared to the west (57, 58, 115). An example is that the high PUFA diets of Korean monks was associated with higher PUFA in visceral fat than in American soldiers whose diet was lower in PUFA (115). The relevance of this to AP outcomes is supported by the correlation between dietary fatty acid composition and adipose tissue fatty acid composition(52, 115) and the findings that unsaturated fatty acids (85, 97), especially PUFAs (34, 83) are relatively more toxic than saturated fatty acids during pancreatitis.

Characteristics of Visceral Fat in Obesity Associated SAP

Total body fat may comprise more than 30% of the body weight in obesity (36). Fat accumulation can occur in the subcutaneous and viseral compartments, and while there are case reports of fat necrosis distant from the pancreas during pancreatitis, including osseous (45, 84) and subcutaneous fat (11, 18, 114) associated with detectable pancreatic lipases (18, 138); the principal fat depots commonly affected in pancreatitis are the intra-abdominal or visceral ones which are in close proximity to the pancreas. The sites of visceral fat deposition include the mesentery, omentum, liver (55, 96), the pancreas and peripancreatic space (8, 90, 107, 110, 113). Visceral fat averages more than 3% body weight in obese humans (24, 30), and thus contributes a large potentially hydrolysable pool for fat necrosis in SAP.

Supporting the human pathologic findings from the 1980's (67, 112), recent studies have noted that both extrapancreatic (6) and intrapancreatic fat necrosis (2, 83) are associated with an increase in severity of pancreatitis. The evidence comes from both radiologic studies (6, 78) and ones using histology of post mortem pancreata (2, 83) to systematically compare pancreatic parenchymal and fat necrosis with the severity of pancreatitis.

Extrapancreatic fat necrosis is a part of necrotizing pancreatitis (9, 40), the revised Atlanta criteria (9), radiographic scoring systems for SAP (e.g. Schroeder and Balthazar) (8, 111), and correlates with worse outcomes during AP (12, 78, 120).

Fat within the pancreas, that is intrapancreatic fat (IPF) has been shown to increase with BMI in studies analyzing autopsy samples (90, 110, 113), surgically resected samples(107), and radiological appearance of the pancreas (74, 110). The distribution of fat is fairly uniform in the dorsal pancreas and is reduced in the ventral pancreas (113). Uneven fatty replacement in the pancreas is infrequent (3.2%), and the pattern of fat distribution is not influenced by obesity (74).

White adipocytes, which are the major cell type comprising visceral fat in obesity, are predominantly composed of triglyceride, which in a pure form has an extremely high concentration of about 1 molar, and forms 80-90% of adipocyte mass (43, 103, 127). As we shall note in the section of pathophysiology, the generation of unsaturated fatty acids from the lipolysis of this triglyceride has been mechanistically associated with adverse outcomes in SAP. Recent studies systematically quantifying the amount of IPF in control pancreata and patients with pancreatitis noted the percentage area occupied by adipocytes correlated with, and significantly increase with BMI (2, 83). Patients with a BMI >30 had significantly higher IPF (18.3 ± 2.3%) compared to those with a BMI <30 (10.2± 1.9%). These values were similar to AP patients in the respective BMI categories suggesting that the amount of IPF does not influence the risk of developing AP. Patients who had SAP associated with pancreatic necrosis however had higher IPF (23.4±4.3%) and BMIs (40.0±2.8 Kg/m^2) compared to those with mild disease (7.8±1.9% and 30.3±2.5 kg/m^2 respectively). As we shall see later, the higher amount of IPF may modify of AP outcomes for the worse.

Interestingly, in contrast to obesity associated IPF, the IPF increase noted in chronic pancreatitis (CP)

(20, 71, 121, 135), is rarely associated with SAP (70, 87, 92). Fatty replacement is commonly known to occur in chronic pancreatic diseases over the course of several years, which in some cases may start in utero (60, 106). These diseases include Shwachman-Diamond syndrome (128), cystic fibrosis (106) and Johannson-Blizzard syndrome (106). While AP may result in mortality over days (6, 91, 136), mortality in CP is rarely attributed to AP (70, 87, 92) over the several years duration of the disease. A recent detailed morphometric analysis comparing AP to CP noted that unlike the IPF associated with obesity which worsens AP, IPF accumulation in CP is independent of BMI (2, 3). Moreover, a large proportion of CP associated fat is walled off by fibrosis from the rest of the pancreatic parenchyma resulting in a reduction of the "lipolytic flux" between adipocytes and acinar cells (discussed in more detail in the pathophysiology section), which during AP causes peri-fat acinar necrosis, contributing to about half of the parenchymal necrosis in obese patients (2, 83).

Chemical analysis of pancreatic fat in normal pancreata has shown an enrichment of unsaturated fatty acids in the pancreatic triglyceride from individuals with higher amounts of pancreatic fat (99) compared to those with lesser amounts. Pancreatic necrosis debridement fluid has a higher concentration of unsaturated fatty acids (34, 83, 85, 93). These observations along with the predisposition of obese patients to have a severe AP attack (1, 22, 37, 42, 89, 95, 100, 109, 117, 119, 149), the higher serum levels of UFAs reported in patients with SAP (123), SAP being reported at lower BMIs from countries with higher UFAs or PUFA in their diets and visceral fat (119, 124, 148, 149) support an association between lipolysis of viseral triglyceride enriched in UFAs with SAP. The mechanisms of this phenomenon are discussed in the section on pathophysiology below.

3. Pathophysiologic Role of Obesity Related Fat in SAP

Adverse outcomes early in the course of the SAP are typically related to distant organ complications such sustained respiratory, renal failure or shock (61, 75, 79). Those later in the disease course are typically associated with complications of severe pancreatic necrosis (19, 41, 44, 82) including infection and the organ failure associated with it. Here we will systematically explore each of these in the context of obesity.


Figure 1: Immunohistochemistry for Perilipin1, showing brown staining adipocytes in the human pancreas. A: The apical lumen of the exocrine pancreatic cells (red ovals) into which pancreatic enzymes are secreted face away from the adipocytes. It is the basal surfaces of the exocrine acinar cells (red dashes) that abut the adjacent adipocytes.

Role of Pancreatic Fat in Exacerbating Pancreatic Necrosis

As detailed in the section above, both histologic and radiologic quantification show Intrapancreatic adipocyte mass to increase with BMI in the human pancreas (2, 83, 110). Unsaturated triglyceride is higher in human pancreata with a larger number of adipocytes (99), and pancreatic necrosis collections from obese patients have higher UFA concentrations than pancreatic fluid from pseudocysts and pancreatic cystic neoplasms (85), which are typically from patients with lower BMIs compared to patients with necrotic collections. These observations along with the epidemiologic data mentioned above associating obesity with SAP supports the need for further mechanistic exploration of this area.

The first question these observations bring is how do pancreatic fat and the exocrine pancreas interact in health and disease? Most obese persons will live life without experiencing an episode of pancreatitis. While adipocytes which accumulate in obesity are adjacent to cells of the exocrine pancreas **(Figure 1A)**, it is the basal surface of the exocrine cells which abuts the adipocytes (red dashed arcs in **Figure 1B**), and the apical lumen into which the exocrine cells pour their secretions (red ovals) is not in contact with the adipocytes. Thus the two compartments do not communicate normally. Paraffin embedded sections show adipocytes in the pancreas to have a clear cytoplasm consistent with the wash out of triglycerides from these cells during processing **(Figure2A)**. In contrast, during AP some adipocytes take on an amorphous blue appearance on Hematoxylin and Eosin staining consistent with fat necrosis **(Figure 2C)** and there is loss of cellular detail of the surrounding exocrine parenchyma, with a morphological appearance of parenchymal necrosis termed peri-fat acinar necrosis (PFAN) (2, 83). Consistent with the observations from the early 20th century of fatty acids generated in fat necrosis being saponified (50), staining of serial sections of these areas for calcium (e.g. using the Von Kossa method) shows intense brown staining of the fat necrosis.


Figure 2: Serial sections of human pancreas stained with Hematoxylin and Eosin (H&E) and calcium (von Kossa). Normally the adipocytes stain as clear empty round areas and the exocrine parenchyma adjacent to the adipocytes retains its morphological detail (A) and is von Kossa negative (B). In pancreatitis fat necrosis of the adipocytes appears amorphous blue (C), with the adjacent parenchyma losing its morphological detail and appearing diffusely pink consistent with necrosis. This is termed peri-fat acinar necrosis (PFAN). Von Kossa staining (D) is intensely positive in the necrotic fat, and adjacent PFAN, with the staining progressively becoming weaker with increasing distance from the fat necrosis. Modified from (2).

Figure 3: Human pancreas staining for macrophage marker CD68. While there are a few CD68 positive cells (red arrows) around the adipocytes in a normal pancreas (A), sections from pancreatitis patients (B) show areas of fat necrosis (red polygon) and surrounding PFAN to have a large increase in CD68 positive cells supporting the pro-inflammatory and ante-mortem nature of fat necrosis.

Interestingly, this brown staining is not restricted to the fat necrosis and is also positive in the necrotic parenchyma in close proximity to the necrosed fat. The staining becomes less intense with increasing distance from the fat necrosis suggestive of spillage of the products of fat necrosis, i.e. free fatty acids (FFAs) into this PFAN (2, 83). The pathophysiologic relevance of this observation is supported by the intense inflammatory reaction and accumulation of CD68 positive macrophages in and around the PFAN, compared to what is normally seen in pancreatic fat **(Figure 3)**. This inflammatory response also supports the ante-mortem nature of pancreatic fat necrosis in humans. Previous immuno-histochemical studies have shown the presence of pancreatic lipases in fat necrosis (38), suggestive of their mechanistic role in fat necrosis. Basolateral leakage of pancreatic enzymes has been mechanistically studied in detail, and while the polarized acinar cells normally pour their exocrine secretions into the lumen, during pancreatitis there is loss of this polarity with basolateral release of digestive enzymes (25, 26). This phenomenon potentially explains the basolateral leakage of lipases into fat during pancreatitis resulting in the ensuing lipolysis of fat, with consequent fat necrosis, generation of

a high concentration of FFAs locally, eventually culminating in PFAN.

Proof of this "lipolytic flux" between acinar cells and adipocytes being relevant to pancreatic injury during AP is provided by studies using a co-culture system of these two cell types. In this system suspension cultures of acinar cells and adipocytes are physically separated into two different compartments by a 3 micron grid, which allows macromolecular diffusion (2, 83) without contamination of one compartment by the other cell type. This system simulating basolateral release, allows for pancreatic lipases to increase in the adipocyte compartment and lipolytic products including FFAs and glycerol generated by hydrolysis of adipocyte triglyceride, to thereby increase in not only the adipocyte compartment, but also to diffuse into the acinar compartment. The increase in FAAs in the acinar compartment causes necrosis of these cells, as evidenced by prevention of FFA increase and necrosis by the lipase inhibitor orlistat. The pathophysiologic relevance of this *in vitro* system is supported by the Von-Kossa positive areas in PFAN noted in histologic sections of human AP [**Figure 2C, D**, (2, 83)], and is proven further by induction of acinar

necrosis by direct exposure to UFAs at concentrations present in human pancreatic necrosis collections (2, 34, 83, 85). Further proof is provided by *in vivo* models in which intraductal injection of the unsaturated triglyceride glyceryl trilinoleate (GTL) results in severe pancreatic necrosis, which is prevented by inhibition of its lipolysis to linoleic acid (34) by orlistat. The mechanism of UFA induced acinar cell necrosis has been shown to be the inhibition of mitochondrial complexes I and V, resulting in a drop in ATP levels (83). While the intermediary signaling involved in this lipolytic flux and fatty acid induced acinar injury described above is yet to be determined, the existing level of evidence regarding the detrimental role of obesity associated fat necrosis in worsening pancreatic necrosis, some of which is cited above is extremely strong. Thus the increase in pancreatic fat during obesity worsens pancreatic necrosis via fat necrosis in those of whom develop AP.

Role of Peri-Pancreatic Fat in Exacerbating Systemic Complications during SAP

Early mortality in SAP, i.e. within the first week, may occur from multisystem organ failure (MSOF) (61, 75, 79) with minimal or no evidence of pancreatic necrosis. Recent clinical reports (6, 12, 111, 120) and the revised Atlanta criteria (9) mention peripancreatic necrosis as a risk factor for SAP. Early severe peri-pancreatic fat stranding is associated with SAP (35, 66) including organ failure, mortality and longer duration of hospital stay (78). While AP associated mortality is currently quoted at 1-3% (98, 139, 145), recent studies show isolated extrapancreatic necrosis with no radiologic evidence of pancreatic necrosis to have mortality rates of 9-13% (6, 78).

Extrapancreatic or peripancreatic necrosis is predominantly fat necrosis around the pancreas (67, 68, 88). Gross and microscopic pathologic studies of surgically resected human pancreata early in the course of pancreatitis were systematically done in the 1980s by different groups including Nordback et al in Finland (88), Kloppel et al (67, 68), and separately by Schmitz-Moormann (112) from the Federal Republic of Germany. Conclusions from these studies supported fat necrosis, especially peri-pancreatic fat necrosis as the earliest lesion in acute pancreatitis. Nordback et al (88) categorically state, "The most vulnerable areas seemed to be the peripancreatic adipose tissue, from where the necrosis spread through the septa towards the pancreatic parenchyma". In their series of 78 patients with acute necrotizing pancreatitis they note that while all patients had peripancreatic necrosis, 10% had peripancreatic necrosis without acinar necrosis. Peripancreatic necrosis involved >50% of the peri-pancreatic fat in 23 of the 30 patients operated within 4 days of presentation, while only 8 of these had >50% of parenchymal necrosis. Supporting the role of systemic injury in SAP associated early mortality (61, 75, 79), autopsy studies showed patients dying within the first week of AP to have lung injury with moderate amount of fat necrosis around the pancreas (104). Overall, this information suggests peri-pancreatic fat necrosis to be a distinct player in the pathogenesis of multisystem organ failure during the initial few days of AP.

Visceral fat, which is the major hydrolyzable pool of triglyceride surrounding the pancreas has been quantified by various groups. It is estimated that this may average more than 3 Kg in persons with a body weight averaging 84 Kg (24, 30). Calculations from imaging studies estimate visceral fat to occupy 10-30% of the intra-abdominal abdominal area (17), and with intra-abdominal volumes of obese individuals estimated to be between 23-30 liters (46), the volume occupied by visceral fat can range from 2-9 liters. Since triglyceride comprises 80-90% of adipocyte volume (43, 103, 127), and each triglyceride molecule can generate three FFA molecules after lipolysis, unregulated leakage of lipases from the pancreas during pancreatitis can potentially generate large amounts of lipotoxic FFAs from these peripancreatic visceral fat depots in a short time and result in adverse outcomes.

Recently mechanistic studies have explored the role of peri-pancreatic fat necrosis in multisystem organ failure. Patel et al noted a classically self-limited model of pancreatitis in mice, i.e. caerulein pancreatitis, to be lethal in obese mice but not lean mice (97). Interestingly they noted that pancreatic acinar necrosis was no different in the groups that survived compared to non-survivors. In contrast, fat necrosis was absent in lean mice, significantly more in obese mice which died, and reduced by treating these mice with the lipase inhibitor orlistat. The most impressive changes at necropsy were noted in the abdominal fat surrounding the pancreas, with fat necrosis and saponification being noted in the mice which died; which resembles human disease. This was associated with hypocalcemia [a SAP marker/predictor included in the Ranson's (101), Glasgow criteria(10) and the Japanese severity score(132)] , lung injury and renal failure (evidenced by elevated BUNs), all of which are commonly used markers or predictors for SAP (10, 48, 101, 141). Further proof of the role of peri-pancreatic fat necrosis in worsening AP outcomes independent of pancreatic necrosis comes from a recent study where triolein [the triglyceride form of the most abundant UFA in humans i.e. oleic acid] when co-administred during the induction of caerulein pancreatitis in lean rats resulted in multisystem organ failure with 97% mortality (85). This was evidenced by hypoxemic respiratory failure (PaO2 < 89%) associated with acute lung injury, renal tubular injury along with elevated serum BUNs; all in the absence of significant pancreatic necrosis. Serum cytokines including IL-1ß and IL-8 in the rats with organ failure were more than 10x elevated than those with caerulein pancreatitis alone. All of the parameters described above are a part of SAP markers (5, 14, 28, 29, 51, 77, 102, 133) or prediction systems (10, 48, 101, 132, 141). To explore this further, the authors exposed peripheral blood mononuclear cells to UFAs IL-1ß +IL-8 (85, 97) and noted that while UFAs at concentrations below those noted in the serum resulted in necro-apoptotic cell death, cytokines at concentrations above those in the serum did not do so. This is consistent with findings that while UFAs can increase mRNA levels of cytokines and induce cell death (2, 83), cytokines do not induce cell injury and in some cases are hypothesized to have a protective role in acute pancreatitis (27, 47) and may do so by reducing systemic injury (13, 64, 105, 144, 147).

It is worth noting that in the studies mentioned above triolein was administered to lean rats and its hydrolysis resulted in high serum levels of its lipolytic product oleic acid (350±294 micromolar), similar to SAP patients with complications (614±146 micromolar) (123). These patients also had serum FFA >1400micromolar (123) which were in the same range as the rats dying with multisystem organ failure (1421 ± 851 micromolar). Thus it is the acute lipotoxicity from UFAs and not the chronic inflammatory state associated with obesity those results in adverse AP outcomes. Further proof of the role of UFAs in SAP comes from studies in which UFAs were administered to rodents in pure form. These showed UFAs to cause acute lung injury (54, 56, 69, 142), renal tubular toxicity (59, 80)renal failure (32, 142), and hypocalcaemia,(32); which is a spectrum of endpoints highly relevant to multisystem organ failure associated with SAP and parameters of which are used in grading AP severity (10, 48, 101, 132, 140, 141). Thus the acute release of large amounts of UFA by lipolysis of the large pools of peri-pancreatic visceral fat can worsen the course of the disease even in cases where there is minimal pancreatic necrosis, such as early in the course of the disease.

4. Summary

In summary we have studied the mechanisms resulting in excessive pancreatic or visceral fat necrosis during AP in obese patients, and how this may change the course of the disease for the worse. This occurs due to lipolysis of the viseral triglyceride by the leaked pancreatic lipases, resulting in a large and acute release of UFAs locally or systemically. The local release results in

inhibition of mitochondrial complexes I and V and pancreatic necrosis, while the systemic UFA release can result lung and renal injury culminating in multisystem organ failure. Thus unregulated lipolysis of visceral fat in obesity can convert acute pancreatitis to SAP.

5. References

1. **Abu Hilal M and Armstrong T**. The impact of obesity on the course and outcome of acute pancreatitis. *Obes Surg* 18(3): 326-328, 2008. PMID: 18202895.
2. **Acharya C, Cline RA, Jaligama D, Noel P, Delany JP, Bae K, et al.** Fibrosis Reduces Severity of Acute-on-Chronic Pancreatitis in Humans. *Gastroenterology* 145(2): 466-475, 2013. PMID: 23684709.
3. **Acharya C, Navina S and Singh VP**. Role of pancreatic fat in the outcomes of pancreatitis. *Pancreatology* 14(5): 403-408, 2014. PMID: 25278311.
4. **Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, et al.** Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. *JOP* 4(1): 41-48, 2003. PMID: 12555015.
5. **Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC and Papachristou GI**. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. *Pancreatology* 9(6): 777-785, 2009. PMID: 20110745.
6. **Bakker OJ, van Santvoort H, Besselink MG, Boermeester MA, van Eijck C, Dejong K, et al.** Extrapancreatic necrosis without pancreatic parenchymal necrosis: a separate entity in necrotising pancreatitis? *Gut* 62(10): 1475-1480, 2013. PMID: 22773550.
7. **Balser W**. Ueber Fettnekrose cine zuwcilen todliche Krankheit des Menschen. *Arch Pathol Anat Physiol* 90: 520-535, 1882.
8. **Balthazar EJ, Robinson DL, Megibow AJ and Ranson JH**. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 174(2): 331-336, 1990. PMID: 2296641.
9. **Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al.** Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 62(1): 102-111, 2013. PMID: 23100216.
10. **Blamey SL, Imrie CW, O'Neill J, Gilmour WH and Carter DC**. Prognostic factors in acute pancreatitis. *Gut* 25(12): 1340-1346, 1984. PMID: 6510766.
11. **Blauvelt H**. A case of acute pancreatitis with subcutaneous fat necrosis. *The British journal of surgery* 34(134): 207, 1946. PMID: 20278132.
12. **Bollen TL, Singh VK, Maurer R, Repas K, van Es HW, Banks PA, et al.** A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. *Am J Gastroenterol* 107(4): 612-619, 2012. PMID: 22186977.
13. **Borjesson A, Norlin A, Wang X, Andersson R and Folkesson HG**. TNF-alpha stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats. *American journal of physiology. Lung cellular and molecular physiology* 278(1): L3-12, 2000. PMID: 10645884.
14. **Brivet FG, Emilie D and Galanaud P**. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. *Crit Care Med* 27(4): 749-755, 1999. PMID: 10321665.
15. **Brown A, James-Stevenson T, Dyson T and Grunkenmeier D**. The panc 3 score: a rapid and accurate test for predicting severity on presentation in acute pancreatitis. *J Clin Gastroenterol* 41(9): 855-858, 2007. PMID: 17881932.
16. **Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al.** Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. *Gastroenterology* 104(4): 1165-1170, 1993. PMID: 8462805.
17. **Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL, et al.** The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. *Obesity* 19(2): 402-408, 2011. PMID: 20948514.
18. **Cannon JR, Pitha JV and Everett MA**. Subcutaneous fat necrosis in pancreatitis. *J Cutan Pathol* 6(6): 501-506, 1979. PMID: 521541.

19. **Carnovale A, Rabitti PG, Manes G, Esposito P, Pacelli L and Uomo G**. Mortality in acute pancreatitis: is it an early or a late event? *JOP* 6(5): 438-444, 2005. PMID: 16186665.
20. **Chaudry G, Navarro OM, Levine DS and Oudjhane K**. Abdominal manifestations of cystic fibrosis in children. *Pediatr Radiol* 36(3): 233-240, 2006. PMID: 16391928.
21. **Chen CH, Dai CY, Hou NJ, Chen SC, Chuang WL and Yu ML**. Etiology, severity and recurrence of acute pancreatitis in southern taiwan. *J Formosan Med Assoc* 105(7): 550-555, 2006. PMID: 16877234.
22. **Chen SM, Xiong GS and Wu SM**. Is obesity an indicator of complications and mortality in acute pancreatitis? An updated meta-analysis. *J Dig Dis* 13(5): 244-251, 2012. PMID: 22500786.
23. **Chiari H**. Uber die Beziehungen zwischen dem Pankreas und der Fettgewebsnekrose. *Zbl Pathol* 17( ): 798-799, 1906.
24. **Choh AC, Demerath EW, Lee M, Williams KD, Towne B, Siervogel RM, et al.** Genetic analysis of self-reported physical activity and adiposity: the Southwest Ohio Family Study. *Public Health Nutrition* 12(8): 1052-1060, 2009. PMID: 18778532.
25. **Cosen-Binker LI, Binker MG, Wang CC, Hong W and Gaisano HY**. VAMP8 is the v-SNARE that mediates basolateral exocytosis in a mouse model of alcoholic pancreatitis. *J Clin Invest* 118(7): 2535-2551, 2008. PMID: 18535671.
26. **Cosen-Binker LI, Lam PP, Binker MG, Reeve J, Pandol S and Gaisano HY**. Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c. *J Biol Chem* 282(17): 13047-13058, 2007. PMID: 17324928.
27. **Cuzzocrea S, Mazzon E, Dugo L, Centorrino T, Ciccolo A, McDonald MC, et al.** Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. *Cytokine* 18(5): 274-285, 2002. PMID: 12161103.
28. **Dambrauskas Z, Giese N, Gulbinas A, Giese T, Berberat PO, Pundzius J, et al.** Different profiles of cytokine expression during mild and severe acute pancreatitis. *World J Gastroenterol* 16(15): 1845-1853. PMID: 20397261.
29. **Daniel P, Lesniowski B, Mokrowiecka A, Jasinska A, Pietruczuk M and Malecka-Panas E**. Circulating levels of visfatin, resistin and pro-inflammatory cytokine interleukin-8 in acute pancreatitis. *Pancreatology* 10(4): 477-482, 2010. PMID: 20720449.
30. **Demerath EW, Reed D, Choh AC, Soloway L, Lee M, Czerwinski SA, et al.** Rapid postnatal weight gain and visceral adiposity in adulthood: the Fels Longitudinal Study. *Obesity* 17(11): 2060-2066, 2009. PMID: 19373221.
31. **Deng LH, Xue P, Xia Q, Yang XN and Wan MH**. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. *World J Gastroenterol* 14(28): 4558-4561, 2008. PMID: 18680239.
32. **Dettelbach MA, Deftos LJ and Stewart AF**. Intraperitoneal free fatty acids induce severe hypocalcemia in rats: a model for the hypocalcemia of pancreatitis. *J Bone Miner Res* 5(12): 1249-1255, 1990. PMID: 2075838.
33. **Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M, et al.** Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. *Int J Pancreatol* 10(3-4): 261-267, 1991. PMID: 1787337.
34. **Durgampudi C, Noel P, Patel K, Cline R, Trivedi RN, DeLany JP, et al.** Acute Lipotoxicity Regulates Severity of Biliary Acute Pancreatitis without Affecting Its Initiation. *Am J Pathol* 184(6): 1773-1784, 2014. PMID: 24854864.
35. **Eatock FC, Brombacher GD, Steven A, Imrie CW, McKay CJ and Carter R**. Nasogastric feeding in severe acute pancreatitis may be practical and safe. *Int J Pancreatol* 28(1): 23-29, 2000. PMID: 11185707.
36. **Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al.** Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 478(7367): 103-109, 2011. PMID: 21909115.
37. **Evans AC, Papachristou GI and Whitcomb DC**. Obesity and the risk of severe acute pancreatitis. *Minerva Gastroenterol Dietol* 56(2): 169-179. PMID: 20485254.
38. **Fallon MB, Gorelick FS, Anderson JM, Mennone A, Saluja A and Steer ML**. Effect of cerulein hyperstimulation on the paracellular barrier of rat exocrine pancreas. *Gastroenterology* 108(6): 1863-1872, 1995. PMID: 7539388.
39. **Fitz RH**. Acute pancreatitis : a consideration of pancreatic hemorrhage, hemorrhagic, suppurative, and gangrenous pancreatitis, and of disseminated fat-necrosis. Boston, Cupples and Hurd, 1889.
40. **Freeman ML, Werner J, van Santvoort HC, Baron TH, Besselink MG, Windsor JA, et al.** Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. *Pancreas* 41(8): 1176-1194, 2012. PMID: 23086243.
41. **Fu CY, Yeh CN, Hsu JT, Jan YY and Hwang TL**. Timing of mortality in severe acute pancreatitis: experience from 643 patients. *World J Gastroenterol* 13(13): 1966-1969, 2007. PMID: 17461498.

42. **Funnell IC, Bornman PC, Weakley SP, Terblanche J and Marks IN**. Obesity: an important prognostic factor in acute pancreatitis. *Br J Surg* 80(4): 484-486, 1993. PMID: 8495317.

43. **Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ and Zamora S**. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans. *Int J Obes* 30(6): 899-905, 2006. PMID: 16446749.

44. **Gloor B, Muller CA, Worni M, Martignoni ME, Uhl W and Buchler MW**. Late mortality in patients with severe acute pancreatitis. *Br J Surg* 88(7): 975-979, 2001. PMID: 11442530.

45. **Goluboff N, Cram R, Ramgotra B, Singh A and Wilkinson GW**. Polyarthritis and bone lesions complicating traumatic pancreatitis in two children. *Canadian Med Assoc J* 118(8): 924-928, 1978. PMID: 647564.

46. **Guerrero-Romero F and Rodriguez-Moran M**. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. *Archives Med Res* 34(5): 428-432, 2003. PMID: 14602511.

47. **Guice KS, Oldham KT, Remick DG, Kunkel SL and Ward PA**. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis. *J Surg Res* 51(6): 495-499, 1991. PMID: 1943086.

48. **Harrison DA, D'Amico G and Singer M**. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. *Critical care medicine* 35(7): 1703-1708, 2007. PMID: 17522578.

49. **Hegazi R, Raina A, Graham T, Rolniak S, Centa P, Kandil H, et al.** Early jejunal feeding initiation and clinical outcomes in patients with severe acute pancreatitis. *JPEN. Journal of parenteral and enteral nutrition* 35(1): 91-96, 2011. PMID: 21224435.

50. **Herbert F**. Pancreatic Fat Necrosis: A Chemical Study. *Br J Exp Pathol* 9(2): 57-63, 1928.

51. **Hirota M, Nozawa F, Okabe A, Shibata M, Beppu T, Shimada S, et al.** Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis. *Pancreas* 21(2): 141-146, 2000. PMID: 10975707.

52. **Hirsch J, Farquhar JW, Ahrens EH, Jr., Peterson ML and Stoffel W**. Studies of adipose tissue in man. A microtechnic for sampling and analysis. *Am J Clin Nutr* 8: 499-511, 1960. PMID: 13714574.

53. **Hotchkiss LW**. VIII. Acute Pancreatitis with Very Extensive Fat Necrosis. *Annals Surg* 56(1): 111-117, 1912. PMID: 17862860.

54. **Hussain N, Wu F, Zhu L, Thrall RS and Kresch MJ**. Neutrophil apoptosis during the development and resolution of oleic acid-induced acute lung injury in the rat. *Am J Respir Cell Mol Biol* 19(6): 867-874, 1998. PMID: 9843920.

55. **Ibrahim MM**. Subcutaneous and visceral adipose tissue: structural and functional differences. *Obes Rev*, 2009. PMID: 19656312.

56. **Inoue H, Nakagawa Y, Ikemura M, Usugi E and Nata M**. Molecular-biological analysis of acute lung injury (ALI) induced by heat exposure and/or intravenous administration of oleic acid. *Legal Med* 14(6): 304-308, 2012. PMID: 22819303.

57. **Insull W, Jr. and Bartsch GE**. Fatty acid composition of human adipose tissue related to age, sex, and race. *Am J Clin Nutr* 20(1): 13-23, 1967. PMID: 6017005.

58. **Insull W, Jr., Lang PD, Hsi BP and Yoshimura S**. Studies of arteriosclerosis in Japanese and American men. I. Comparison of fatty acid composition of adipose tissue. *J Clin Invest* 48(7): 1313-1327, 1969. PMID: 5794253.

59. **Ishola DA, Jr., Post JA, van Timmeren MM, Bakker SJ, Goldschmeding R, Koomans HA, et al.** Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells. *Kidney Int* 70(4): 724-731, 2006. PMID: 16837928.

60. **Jackson WD**. Pancreatitis: etiology, diagnosis, and management. *Current opinion in pediatrics* 13(5): 447-451, 2001. PMID: 11801891.

61. **Johnson CD and Abu-Hilal M**. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. *Gut* 53(9): 1340-1344, 2004. PMID: 15306596.

62. **Johnson CD, Toh SK and Campbell MJ**. Combination of APACHE-II score and an obesity score (APACHE-O) for the prediction of severe acute pancreatitis. *Pancreatology* 4(1): 1-6, 2004. PMID: 14988652.

63. **Katuchova J, Bober J, Harbulak P, Hudak A, Gajdzik T, Kalanin R, et al.** Obesity as a risk factor for severe acute pancreatitis patients. *Wiener klinische Wochenschrift* 126(7-8): 223-227, 2014. PMID: 24522641.

64. **Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M, et al.** Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. *Am J Physiol Lung Cell Mol Physiol* 288(2): L342-349, 2005. PMID: 15475383.

65. **Kimura W, Meyer F, Hess D, Kirchner T, Fischbach W and Mossner J**. Comparison of different treatment modalities in experimental pancreatitis in rats. *Gastroenterology* 103(6): 1916-1924, 1992. PMID: 1451985.

66. **King NK, Powell JJ, Redhead D and Siriwardena AK**. A simplified method for computed tomographic estimation of prognosis in acute pancreatitis. *Scand J Gastroenterol* 38(4): 433-436, 2003. PMID: 12739717.
67. **Kloppel G, Dreyer T, Willemer S, Kern HF and Adler G**. Human acute pancreatitis: its pathogenesis in the light of immunocytochemical and ultrastructural findings in acinar cells. *Virchows Arch A Pathol Anat Histopathol* 409(6): 791-803, 1986. PMID: 3094241.
68. **Kloppel G vGR, Dreyer T**. Pathomorphology of acute pancreatitis. Analysis of 367 autopsy cases and 3 surgical specimens. Amsterdam, New York, Oxford, 1984.
69. **Lai JP, Bao S, Davis IC and Knoell DL**. Inhibition of the phosphatase PTEN protects mice against oleic acid-induced acute lung injury. *Br J Pharmacol* 156(1): 189-200, 2009. PMID: 19134000.
70. **Lankisch PG, Breuer N, Bruns A, Weber-Dany B, Lowenfels AB and Maisonneuve P**. Natural history of acute pancreatitis: a long-term population-based study. *Am J Gastroenterol* 104(11): 2797-2805; quiz 2806, 2009. PMID: 19603011.
71. **LaRusch J and Whitcomb DC**. Genetics of pancreatitis. *Curr Opin Gastroenterol* 27(5): 467-474. PMID: 21844754.
72. **Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, et al.** Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. *Pancreas* 37(1): 13-12, 2008. PMID: 18580438.
73. **Martinez J, Sanchez-Paya J, Palazon JM, Aparicio JR, Pico A and Perez-Mateo M**. Obesity: a prognostic factor of severity in acute pancreatitis. *Pancreas* 19(1): 15-20, 1999. PMID: 10416686.
74. **Matsumoto S, Mori H, Miyake H, Takaki H, Maeda T, Yamada Y, et al.** Uneven fatty replacement of the pancreas: evaluation with CT. *Radiology* 194(2): 453-458, 1995. PMID: 7824726.
75. **McKay CJ, Evans S, Sinclair M, Carter CR and Imrie CW**. High early mortality rate from acute pancreatitis in Scotland, 1984-1995. *Br J Surg* 86(10): 1302-1305, 1999. PMID: 10540138.
76. **Mery CM, Rubio V, Duarte-Rojo A, Suazo-Barahona J, Pelaez-Luna M, Milke P, et al.** Android fat distribution as predictor of severity in acute pancreatitis. *Pancreatology* 2(6): 543-549, 2002. PMID: 12435867.
77. **Messmann H, Vogt W, Falk W, Vogl D, Zirngibl H, Leser HG, et al.** Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis. *Eur J Gastroenterol Hepatol* 10(7): 611-617, 1998. PMID: 9855088.
78. **Meyrignac O, Lagarde S, Bournet B, Mokrane FZ, Buscail L, Rousseau H, et al.** Acute Pancreatitis: Extrapancreatic Necrosis Volume as Early Predictor of Severity. *Radiology*: 141494, 2015. PMID: 25642743.
79. **Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ and Parks RW**. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. *Br J Surg* 93(6): 738-744, 2006. PMID: 16671062.
80. **Moran JH, Nowak G and Grant DF**. Analysis of the toxic effects of linoleic acid, 12,13-cis-epoxyoctadecenoic acid, and 12,13-dihydroxyoctadecenoic acid in rabbit renal cortical mitochondria. *Toxicol Appl Pharmacol* 172(2): 150-161, 2001. PMID: 11298501.
81. **Mossner J, Bodeker H, Kimura W, Meyer F, Bohm S and Fischbach W**. Isolated rat pancreatic acini as a model to study the potential role of lipase in the pathogenesis of acinar cell destruction. *Int J Pancreatol* 12(3): 285-296, 1992. PMID: 1289421.
82. **Mutinga M, Rosenbluth A, Tenner SM, Odze RR, Sica GT and Banks PA**. Does mortality occur early or late in acute pancreatitis? *Int J Pancreatol* 28(2): 91-95, 2000. PMID: 11128978.
83. **Navina S, Acharya C, DeLany JP, Orlichenko LS, Baty CJ, Shiva SS, et al.** Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. *Science translational medicine* 3(107): 107ra110, 2011. PMID: 22049070.
84. **Neuer FS, Roberts FF and McCarthy V**. Osteolytic lesions following traumatic pancreatitis. *Am J Dis Child* 131(7): 738-740, 1977. PMID: 879110.
85. **Noel P, Patel K, Durgampudi C, Trivedi RN, de Oliveira C, Crowell MD, et al.** Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections. *Gut*, 2014. PMID: 25500204.
86. **Nojgaard C, Becker U, Matzen P, Andersen JR, Holst C and Bendtsen F**. Progression from acute to chronic pancreatitis: prognostic factors, mortality, and natural course. *Pancreas* 40(8): 1195-1200. PMID: 21926938.
87. **Nojgaard C, Matzen P, Bendtsen F, Andersen JR, Christensen E and Becker U**. Factors associated with long-term mortality in acute pancreatitis. *Scand J Gastroenterol* 46(4): 495-502. PMID: 21091094.
88. **Nordback I and Lauslahti K**. Clinical pathology of acute necrotising pancreatitis. *J Clin Path* 39(1): 68-74, 1986. PMID: 3950033.

89. **O'Leary DP, O'Neill D, McLaughlin P, O'Neill S, Myers E, Maher MM, et al.** Effects of abdominal fat distribution parameters on severity of acute pancreatitis. *World J Surg* 36(7): 1679-1685, 2012. PMID: 22491816.

90. **Olsen TS**. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. *Acta Pathol Microbiol Scand A* 86A(5): 367-373, 1978. PMID: 716899.

91. **Omdal T, Dale J, Lie SA, Iversen KB, Flaatten H and Ovrebo K**. Time trends in incidence, etiology, and case fatality rate of the first attack of acute pancreatitis. *Scand J Gastroenterol* 46(11): 1389-1398. PMID: 21830851.

92. **Otsuki M**. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. *J Gastroenterol* 38(4): 315-326, 2003. PMID: 12743770.

93. **Panek J, Sztefko K and Drozdz W**. Composition of free fatty acid and triglyceride fractions in human necrotic pancreatic tissue. *Med Sci Monit* 7(5): 894-898, 2001. PMID: 11535930.

94. **Pannala R, Kidd M and Modlin IM**. Acute pancreatitis: a historical perspective. *Pancreas* 38(4): 355-366, 2009. PMID: 19390402.

95. **Papachristou GI, Papachristou DJ, Avula H, Slivka A and Whitcomb DC**. Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response. *Pancreatology* 6(4): 279-285, 2006. PMID: 16636600.

96. **Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, et al.** Visceral adipose tissue area is an independent risk factor for hepatic steatosis. *J Gastroenterol Hepatol* 23(6): 900-907, 2008. PMID: 17995942.

97. **Patel K, Trivedi RN, Durgampudi C, Noel P, Cline RA, DeLany JP, et al.** Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation. *Am J Pathol* 185(3): 808-819, 2015. PMID: 25579844.

98. **Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al.** Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 143(5): 1179-1187 e1171-1173, 2012. PMID: 22885331.

99. **Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A and Fielding BA**. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. *Obesity (Silver Spring)* 16(3): 522-530, 2008. PMID: 18239594.

100. **Porter KA and Banks PA**. Obesity as a predictor of severity in acute pancreatitis. *Int J Pancreatol* 10(3-4): 247-252, 1991. PMID: 1787336.

101. **Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K and Spencer FC**. Prognostic signs and the role of operative management in acute pancreatitis. *Surg Gynecol Obstet* 139(1): 69-81, 1974. PMID: 4834279.

102. **Regner S, Appelros S, Hjalmarsson C, Manjer J, Sadic J and Borgstrom A**. Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. *Pancreatology* 8(1): 42-49, 2008. PMID: 18235216.

103. **Ren J, Dimitrov I, Sherry AD and Malloy CR**. Composition of adipose tissue and marrow fat in humans by 1H NMR at 7 Tesla. *J Lipid Res* 49(9): 2055-2062, 2008. PMID: 18509197.

104. **Renner IG, Savage WT, 3rd, Pantoja JL and Renner VJ**. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. *Dig Dis Sci* 30(10): 1005-1018, 1985. PMID: 3896700.

105. **Rezaiguia S, Garat C, Delclaux C, Meignan M, Fleury J, Legrand P, et al.** Acute bacterial pneumonia in rats increases alveolar epithelial fluid clearance by a tumor necrosis factor-alpha-dependent mechanism. *J Clin Invest* 99(2): 325-335, 1997. PMID: 9006001.

106. **Robertson MB, Choe KA and Joseph PM**. Review of the abdominal manifestations of cystic fibrosis in the adult patient. *Radiographics : a review publication of the Radiological Society of North America, Inc* 26(3): 679-690, 2006. PMID: 16702447.

107. **Rosso E, Casnedi S, Pessaux P, Oussoultzoglou E, Panaro F, Mahfud M, et al.** The role of "fatty pancreas" and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. *J Gastrointest Surg* 13(10): 1845-1851, 2009. PMID: 19639369.

108. **Ruixing Y, Qiming F, Dezhai Y, Shuquan L, Weixiong L, Shangling P, et al.** Comparison of demography, diet, lifestyle, and serum lipid levels between the Guangxi Bai Ku Yao and Han populations. *J Lipid Res* 48(12): 2673-2681, 2007. PMID: 17890682.

109. **Sadr-Azodi O, Orsini N, Andren-Sandberg A and Wolk A**. Abdominal and total adiposity and the risk of acute pancreatitis: a population-based prospective cohort study. *Am J Gastroenterol* 108(1): 133-139, 2013. PMID: 23147519.

110. **Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al.** Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. *Clin Anat* 20(8): 933-942, 2007. PMID: 17879305.

111. **Schaffler A, Hamer O, Dickopf J, Goetz A, Landfried K, Voelk M, et al.** Admission resistin levels predict peripancreatic necrosis and clinical severity in acute pancreatitis. *Am J Gastroenterol* 105(11): 2474-2484, 2010. PMID: 20648005.

112. **Schmitz-Moormann P**. Comparative radiological and morphological study of the human pancreas. IV. Acute necrotizing pancreatitis in man. *Pathol Res Pract* 171(3-4): 325-335, 1981. PMID: 7279784.

113. **Schmitz-Moormann P, Pittner PM and Heinze W**. Lipomatosis of the pancreas. A morphometrical investigation. *Pathol Res Pract* 173(1-2): 45-53, 1981. PMID: 7335549.

114. **Schrier RW, Melmon KL and Fenster LF**. Subcutaneous nodular fat necrosis in pancreatitis. *Arch Intern Med* 116(6): 832-836, 1965. PMID: 5848214.

115. **Scott RF, Lee KT, Kim DN, Morrison ES and Goodale F**. Fatty Acids of Serum and Adipose Tissue in Six Groups Eating Natural Diets Containing 7 to 40 Per Cent Fat. *Am J Clin Nutr* 14: 280-290, 1964. PMID: 14157830.

116. **Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al.** JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. *J Hepatobiliary Pancreat Surg* 13(1): 10-24, 2006. PMID: 16463207.

117. **Sempere L, Martinez J, de Madaria E, Lozano B, Sanchez-Paya J, Jover R, et al.** Obesity and fat distribution imply a greater systemic inflammatory response and a worse prognosis in acute pancreatitis. *Pancreatology* 8(3): 257-264, 2008. PMID: 18497538.

118. **Seta T, Noguchi Y, Shimada T, Shikata S and Fukui T**. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. *Eur J Gastroenterol Hepatol* 16(12): 1287-1293, 2004. PMID: 15618834.

119. **Shin KY, Lee WS, Chung DW, Heo J, Jung MK, Tak WY, et al.** Influence of obesity on the severity and clinical outcome of acute pancreatitis. *Gut and liver* 5(3): 335-339, 2011. PMID: 21927663.

120. **Singh VK, Bollen TL, Wu BU, Repas K, Maurer R, Yu S, et al.** An assessment of the severity of interstitial pancreatitis. *Clin Gastroenterol Hepatol* 9(12): 1098-1103, 2011. PMID: 21893128.

121. **Soyer P, Spelle L, Pelage JP, Dufresne AC, Rondeau Y, Gouhiri M, et al.** Cystic fibrosis in adolescents and adults: fatty replacement of the pancreas--CT evaluation and functional correlation. *Radiology* 210(3): 611-615, 1999. PMID: 10207457.

122. **Storck G**. Experimental fat necrosis in the rat. I. Studies with the vital microscope. *Acta Chir Scand* 138(1): 69-77, 1972. PMID: 5036400.

123. **Sztefko K and Panek J**. Serum free fatty acid concentration in patients with acute pancreatitis. *Pancreatology* 1(3): 230-236, 2001. PMID: 12120200.

124. **Thandassery RB, Appasani S, Yadav TD, Dutta U, Indrajit A, Singh K, et al.** Implementation of the Asia-Pacific Guidelines of Obesity Classification on the APACHE-O Scoring System and Its Role in the Prediction of Outcomes of Acute Pancreatitis: A Study from India. *Dig Dis Sci*, 2013. PMID: 24374646.

125. **Theve NO**. Studies in fat necrosis. V. Effect of glucose and insulin on fat necrosis in rats with experimental pancreatitis. *Acta Chir Scand* 139(6): 507-509, 1973. PMID: 4753098.

126. **Theve NO, Hallberg D and Carlstrom A**. Studies in fat necrosis. I. Lipolysis and calcium content in adipose tissue from rats with experimentally induced fat necrosis. *Acta chirurgica Scandinavica* 139(2): 131-133, 1973. PMID: 4718164.

127. **Thomas LW**. The chemical composition of adipose tissue of man and mice. *Q J Exp Physiol Cogn Med Sci* 47: 179-188, 1962. PMID: 13920823.

128. **Toiviainen-Salo S, Raade M, Durie PR, Ip W, Marttinen E, Savilahti E, et al.** Magnetic resonance imaging findings of the pancreas in patients with Shwachman-Diamond syndrome and mutations in the SBDS gene. *J Pediatr* 152(3): 434-436, 2008. PMID: 18280855.

129. **Trapnell JE, Rigby CC, Talbot CH and Duncan EH**. A controlled trial of Trasylol in the treatment of acute pancreatitis. *Br J Surg* 61(3): 177-182, 1974. PMID: 4595174.

130. **Trapnell JE, Rigby CC, Talbot CH and Duncan EH**. Proceedings: Aprotinin in the treatment of acute pancreatitis. *Gut* 14(10): 828, 1973. PMID: 4586085.

131. **Trapnell JE, Talbot CH and Capper WM**. Trasylol in acute pancreatitis. *Am J Dig Dis* 12(4): 409-412, 1967. PMID: 5336018.

132. **Ueda T, Takeyama Y, Yasuda T, Kamei K, Satoi S, Sawa H, et al.** Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. *J Gastroenterol* 44(5): 453-459, 2009. PMID: 19308309.

133. **Ueda T, Takeyama Y, Yasuda T, Matsumura N, Sawa H, Nakajima T, et al.** Significant elevation of serum interleukin-18 levels in patients with acute pancreatitis. *J Gastroenterol* 41(2): 158-165, 2006. PMID: 16568375.

134. **Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, et al.** Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. *Hypertension* 50(2): 313-319, 2007. PMID: 17548718.
135. **Vaughn DD, Jabra AA and Fishman EK**. Pancreatic disease in children and young adults: evaluation with CT. *Radiographics* 18(5): 1171-1187, 1998. PMID: 9747614.
136. **Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, et al.** Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include "moderately severe acute pancreatitis". *Am J Gastroenterol* 104(3): 710-715, 2009. PMID: 19262525.
137. **Vidarsdottir H, Moller PH, Thorarinsdottir H and Bjornsson ES**. Acute pancreatitis: a prospective study on incidence, etiology, and outcome. *Eur J Gastroenterol Hepatol* 25(9): 1068-1075, 2013. PMID: 23839162.
138. **Wilson HA, Askari AD, Neiderhiser DH, Johnson AM, Andrews BS and Hoskins LC**. Pancreatitis with arthropathy and subcutaneous fat necrosis. Evidence for the pathogenicity of lipolytic enzymes. *Arthritis Rheum* 26(2): 121-126, 1983. PMID: 6337595.
139. **Wormer BA, Swan RZ, Williams KB, Bradley JF, 3rd, Walters AL, Augenstein VA, et al.** Outcomes of pancreatic debridement in acute pancreatitis: analysis of the nationwide inpatient sample from 1998 to 2010. *Am J Surg* 208(3): 350-362, 2014. PMID: 24933665.
140. **Wu BU, Johannes RS, Sun X, Conwell DL and Banks PA**. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. *Gastroenterology* 137(1): 129-135, 2009. PMID: 19344722.
141. **Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL and Banks PA**. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 57(12): 1698-1703, 2008. PMID: 18519429.
142. **Wu RP, Liang XB, Guo H, Zhou XS, Zhao L, Wang C, et al.** Protective effect of low potassium dextran solution on acute kidney injury following acute lung injury induced by oleic acid in piglets. *Chin Med Sci J* 125(17): 3093-3097, 2012. PMID: 22932187.
143. **Xin MJ, Chen H, Luo B and Sun JB**. Severe acute pancreatitis in the elderly: etiology and clinical characteristics. *World J Gastroenterol* 14(16): 2517-2521, 2008. PMID: 18442198.
144. **Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al.** IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. *J Clin Invest* 101(2): 311-320, 1998. PMID: 9435302.
145. **Yadav D and Lowenfels AB**. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144(6): 1252-1261, 2013. PMID: 23622135.
146. **Yadav D, O'Connell M and Papachristou GI**. Natural history following the first attack of acute pancreatitis. *Am J Gastroenterol* 107(7): 1096-1103. PMID: 22613906.
147. **Yan C, Naltner A, Martin M, Naltner M, Fangman JM and Gurel O**. Transcriptional stimulation of the surfactant protein B gene by STAT3 in respiratory epithelial cells. *J Biol Chem* 277(13): 10967-10972, 2002. PMID: 11788590.
148. **Yang F, Wu H, Li Y, Li Z, Wang C, Yang J, et al.** Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. *Pancreas* 41(8): 1206-1212, 2012. PMID: 23086244.
149. **Yashima Y, Isayama H, Tsujino T, Nagano R, Yamamoto K, Mizuno S, et al.** A large volume of visceral adipose tissue leads to severe acute pancreatitis. *Am J Gastroenterol* 46(10): 1213-1218, 2011. PMID: 21805069.